Short Interest in Entero Therapeutics, Inc. (NASDAQ:ENTO) Drops By 51.4%

Entero Therapeutics, Inc. (NASDAQ:ENTO) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 104,400 shares, a decrease of 51.4% from the December 15th total of 214,800 shares. Based on an average daily volume of 275,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 2.2% of the shares of the company are sold short.

Entero Therapeutics Trading Up 3.4 %

ENTO stock traded up $0.02 during midday trading on Tuesday, reaching $0.56. 21,533 shares of the company were exchanged, compared to its average volume of 58,617. Entero Therapeutics has a one year low of $0.19 and a one year high of $9.35. The business has a 50-day moving average price of $0.58 and a two-hundred day moving average price of $0.59.

Entero Therapeutics (NASDAQ:ENTO) last released its earnings results on Monday, October 21st. The company reported ($3.37) earnings per share (EPS) for the quarter. Equities analysts anticipate that Entero Therapeutics will post -1.13 EPS for the current year.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.